<div id="readability-page-1"><div> RTI opioid treatment program-level measures of retention highlight opportunities for quality improvementRESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 /PRNewswire/ -- A new study published in JAMA Network Open and authored by experts at RTI International, an independent scientific research institute, has found that many opioid treatment programs (OTPs) across the U.S. are struggling to keep patients engaged. According to the study, at typical opioid treatment programs, 61% of Medicaid patients remained in care beyond the first month, but, among the bottom quarter of programs, only 40% remained in treatment for at least one month.&#34;For opioid use disorder, treatment retention is one of the strongest predictors of recovery and survival for patients experiencing opioid use disorder,&#34; said lead author Tami Mark, Ph.D., a Distinguished Fellow at RTI. &#34;This new measure offers OTPs a consistent benchmark that shows how their retention rates align with national patterns, enabling programs to pinpoint strengths, isolate gaps and prioritize targeted improvements.&#34;RTI researchers created case-mix adjusted retention measures using Medicaid claims data from 2018 to 2023. In 2023, the measures included more than 1,100 OTPs, 432,000 treatment episodes, and 261,000 patients.The measures reveal a wide variation in OTPs' retention rates:<ul><li>OTPs in the top 75% retained 73.5% of participants for 30 days, compared with 40.9% in the bottom 25%.</li><li>At 90 days, top OTPs retained 54.8%, while bottom–quartile programs retained 22.2%.</li><li>At 180 days, retention was 40.5% in the top group and 11.4% in the bottom group.</li></ul>RTI researchers Dylan DeLisle, MPH, Chelsea Katz, Ph.D.; William Dowd, Ph.D.; Daniel Barch, Ph.D.; Marianne Kluckman, MPH, also contributed to the study, which was supported by the NIH HEAL Initiative.Read the full studyLearn more about RTI's substance use researchAbout RTI InternationalRTI International is an independent scientific research institute dedicated to improving the human condition. Our vision is to address the world's most critical problems with technical and science-based solutions in pursuit of a better future. Clients rely on us to answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across social, statistical, data, and laboratory sciences, engineering, and other technical disciplines to solve the world's most challenging problems. For more information, visit www.rti.org.Media Contact: RTI International Media Relations 408153@email4pr.com 919-541-7300 <img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wMS0yMyZzbj1QSDcwMDMz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="16" height="16" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wMS0yMyZzbj1QSDcwMDMz"/> View original content:https://www.prnewswire.com/news-releases/new-quality-measures-reveal-wide-variation-in-opioid-treatment-programs-medicaid-patient-retention-rates-302669211.htmlSOURCE RTI International</div></div>

RTI International 在 JAMA Network Open 上發佈的一項研究揭示了美國阿片類藥物治療項目（OTPs）中醫療補助患者保留率的顯著差異。研究表明，僅有 61% 的醫療補助患者在第一個月後繼續接受治療，而排名最低的 25% 的項目僅保留了 40% 的患者。該研究強調了治療保留作為阿片類藥物使用障礙患者康復和生存的預測指標的重要性。研究結果建議，OTPs 可以利用這些基準來識別患者參與度改善的領域

New Quality Measures Reveal Wide Variation in Opioid Treatment Programs' Medicaid Patient Retention Rates

MorningStar

醫療業 3 倍做多 - Direxion

納斯達克生物科技指數 ETF - iShares Nasdaq

醫療業 ETF - Vanguard

Iovance生物治療

Invesco S&P 500 Equal Weight Health Care ETF

阿爾凱默斯

醫藥突破 ETF - ALPS

Invesco Nasdaq Biotechnology ETF

醫療業 ETF - SPDR

Elevance Health

Molina醫療

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

Phibro Animal Health

標普全球醫療股指數 ETF - iShares

美國制藥 ETF - iShares

標普生物技術 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

康西哥

Hookipa Pharma

2 倍做空衞生保健 ETF - ProShares

聯合健康

阿卡迪亞醫療保健

西維斯

Leverage Shares 2X Long UNH Daily ETF

標普醫療保健服務 ETF - SPDR

美國醫療保健供應商 ETF - iShares

生物科技 ETF - VanEck Vectors

Indivior

新的質量措施揭示了阿片類藥物治療項目中醫療補助患者保留率的顯著差異